Fig. 14From: Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s diseaseDesign strategy of the target compounds of series A, B and CBack to article page